ReAlta Life Sciences

ReAlta Life Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare and life-threatening diseases. Their proprietary technology platform, PIC1, harnesses the power of the immune system to address these conditions. ReAlta is developing treatments for rare diseases with limited treatment options. They are exploring therapies for conditions characterized by excessive inflammation. ReAlta Life Sciences’ lead product, RLS-0071, is a complement inhibitor being developed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disorder.

Jobs: